Given their current CEO’s experience with Sonic healthcare and the backing/funding from Medibank for their MDMA psychedelic program, partnership with University of WA, Department of VA commencing funding for psychedelic assisted therapy and Euroz Hartley’s research coverage puts them at a target price of $0.17. Yes they are at a net loss, revenue pretty low and EPS still negative but have abit of net cash. Just want thoughts on this speccy stock.